HIF1A and neoplasm: In the present study, we used the glucose analog 2-DG and the pharmacological Hsp90 inhibitor 17-AAG, which destabilizes the HIF-1α protein and disrupts STAT3-HIF-1α activation axis, to limit IMQ-induced aerobic glycolysis to enhance the anti-tumor activity of IMQ.